Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044473
Status:
COMPLETED
Last Update Posted:
2011-06-08
First Post:
2002-08-29
Brief Title:
A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat
Sponsor:
Johnson Johnson Pharmaceutical Research Development LLC
Organization:
Johnson Johnson Pharmaceutical Research Development LLC
Study Overview
Official Title:
An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the rate of elimination of bacteria by levofloxacin in middle ear fluid of children with a rapid and severe onset of infection and inflammation of the middle ear who are at high risk for infections that are difficult to treat
Detailed Description:
Rapid and severe onset of middle ear infection is a common bacterial infection in children These infections particularly when they occur early in life and are recurrent are associated with considerable disease and can lead to increasingly serious infections This is a multicenter study to determine the effectiveness of levofloxacin in eliminating bacteria in the middle ear fluid of children between 6 months and 5 years of age with a rapid and severe onset of infection and inflammation of the middle ear who are at high risk for infections that are difficult to treat The study consists of a 1-day screening period when patients will be tested for eligibility for the study a 4 to 6-day treatment blood collection possible collection of fluid from the middle ear and assessment period and a post-treatment period to assess the status of the middle ear infection All patients will receive levofloxacin 2 times daily up to a maximum daily dose of 500 mg mixed with liquid and taken by mouth for 10 days Safety evaluations will include laboratory tests physical examinations vital sign measurements and recording of adverse events including any report of joint pain or signs and symptoms of joint disease Effectiveness will be assessed by the rate of elimination of the bacteria identified at the start of the study and by signs and symptoms as well as microscopic evidence that the patient is cured of the middle ear infection The study hypothesis is that levofloxacin will be effective in eliminating bacteria in the middle ear fluid of children with a rapid and severe onset of infection and inflammation of the middle ear and who are at high risk for infections that are difficult to treat Levofloxacin 10 milligramskilogram mgkg 2 times daily up to a maximum daily dose of 500 mg mixed with liquid and taken by mouth for 10 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None